Loading stock data…
Genelux Corporation (GNLX)
$2.54+0.10 (+4.10%)
Market ClosedLast close Sep 8
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genelux Corporation in the Healthcare sector is trading at $2.54 with a market capitalization of $133M. Wall Street consensus targets $19.00 (5 analysts), implying a +648.0% move over the next 12 months. The stock is currently near its 52-week low of $2.29, remaining 16.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +648.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $8,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.17M↑ | -$9.41M↓ | -$8.19M↓ | -$7.79M↑ | -$7.82M |
| Net Income | -$8.93M↑ | -$9.25M↓ | -$7.95M↓ | -$7.46M↑ | -$7.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimul...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$132.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-146.51%
Volume
Today's trading volume
408,290
Recent News
Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value
Key Insights The considerable ownership by retail investors in Genelux indicates that they collectively have a greater...
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...